
Nyxoah SA (NYXH) Stock Forecast & Price Target
Nyxoah SA (NYXH) Analyst Ratings
Bulls say
Nyxoah is a health-technology company with a positive outlook due to several key factors: a successful US launch with strong Q2 results and the addition of 15 new sales reps, a software upgrade for their Genio system that will track sleep quality and compliance, progress towards FDA approval for a new indication, and a planned pursuit of a new CPT code for reimbursement. In addition, the company has introduced revenue guidance for FY26 above street expectations and has multiple pathways for future growth, including a pending catalyst with the results of their ACCCESS trial. This, combined with the positive data points and increased sales force, leads to an optimistic 2026 outlook with potential for increased market share and revenue.
Bears say
Nyxoah is showing strong revenue growth at +499% y/y and +13% q/q in Q1, but its gross margin and opex spend were below estimates, indicating potential issues with profitability. The company also faces standard adoption risks as it competes against market leader Inspire Medical Systems and must obtain additional capital to sustain its cash-burn-heavy business. There is potential for regulatory risks as the company awaits completion of its ACCCESS study, which is a key catalyst for further success.
This aggregate rating is based on analysts' research of Nyxoah SA and is not a guaranteed prediction by Public.com or investment advice.
Nyxoah SA (NYXH) Analyst Forecast & Price Prediction
Start investing in Nyxoah SA (NYXH)
Order type
Buy in
Order amount
Est. shares
0 shares